We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genetics of Hemophilia Mystery Solved

By LabMedica International staff writers
Posted on 25 Mar 2013
The third and final missing piece in the genetic puzzle of an unusual form of hemophilia has been found which could help improve the comprehension of other blood-clotting conditions such as thrombosis.

Hemophilia B Leyden is an X-linked recessive blood-clotting disorder that affects approximately 1 in every 30,000 males and it is also infamously known as the ‘‘royal disease’’ because it afflicted European royal families descended from Queen Victoria.

Geneticists at the University of New South Wales (Kensington, Australia) studied mutations that arise in coagulation factor IX (F9). More...
Mutations within the F9 promoter are associated with the hemophilia B Leyden subtype in which symptoms ameliorate after puberty. Symptoms improve in young men after puberty because a different protein that responds to the hormone testosterone is able to bind to the DNA and boost the gene’s production of clotting factor IX. The disease affects about 80 families worldwide.

The scientists established that the missing regulators in hemophilia B Leyden are the ONECUT transcription factors ONECUT1 and ONECUT2. These proteins bind to the proximal promoter and drive expression of F9. ONECUT1 is also known as hepatocyte nuclear factor 6 (HNF6), while ONECUT2 is known either as hepatocyte nuclear factor 6-beta or one cut homeobox 2. The different Leyden mutations disrupt ONECUT binding to varying degrees in a manner that correlates well with their clinical severities.

Merlin Crossley, PhD, the dean of science at University of New South Wales and senior author of the study, said, “Science is advanced by people who get caught up in puzzles that are important to them and they never forget them. Curious investigators never give up.” Professor Crossley had previously found the two sets of mutations that prevent two key proteins from attaching to the DNA, which turns the gene off as a result. The study was published on March 7, 2013, in the American Journal of Human Genetics.

Related Links:

University of New South Wales





Gold Member
STI Test
Vivalytic MG, MH, UP/UU
Online QC Software
Acusera 24•7
Thyroid Test
Anti-Thyroid EIA Test
POC Immunoassay Analyzer
Procise DX
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.